MA71214A - Méthodes de traitement du cancer par administration d'un inhibiteur de pd-1 - Google Patents
Méthodes de traitement du cancer par administration d'un inhibiteur de pd-1Info
- Publication number
- MA71214A MA71214A MA71214A MA71214A MA71214A MA 71214 A MA71214 A MA 71214A MA 71214 A MA71214 A MA 71214A MA 71214 A MA71214 A MA 71214A MA 71214 A MA71214 A MA 71214A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor
- administration
- methods
- treating cancer
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070401P | 2020-08-26 | 2020-08-26 | |
| US202063094438P | 2020-10-21 | 2020-10-21 | |
| EP21773221.3A EP4204592A1 (fr) | 2020-08-26 | 2021-08-25 | Méthodes de traitement du cancer par administration d'un inhibiteur de pd-1 |
| PCT/US2021/047442 WO2022046833A1 (fr) | 2020-08-26 | 2021-08-25 | Méthodes de traitement du cancer par administration d'un inhibiteur de pd-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71214A true MA71214A (fr) | 2025-04-30 |
Family
ID=77822032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71214A MA71214A (fr) | 2020-08-26 | 2021-08-25 | Méthodes de traitement du cancer par administration d'un inhibiteur de pd-1 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230323470A1 (fr) |
| EP (1) | EP4204592A1 (fr) |
| JP (1) | JP2023540217A (fr) |
| KR (1) | KR20230056761A (fr) |
| CN (1) | CN116134155A (fr) |
| AU (1) | AU2021332246A1 (fr) |
| CA (1) | CA3168743A1 (fr) |
| IL (1) | IL300328A (fr) |
| MA (1) | MA71214A (fr) |
| MX (1) | MX2023002123A (fr) |
| WO (1) | WO2022046833A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025106794A1 (fr) * | 2023-11-16 | 2025-05-22 | Quest Diagnostics Investments Llc | Évaluation de la charge de mutation somatique et sélection de patient |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL147972A0 (en) | 1999-08-23 | 2002-09-12 | Dana Farber Cancer Inst Inc Ge | Pd-1, a receptor for b7-4 and uses therefor |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| CN103059138B (zh) | 2005-05-09 | 2015-10-28 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| WO2007005874A2 (fr) | 2005-07-01 | 2007-01-11 | Medarex, Inc. | Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1) |
| EP3222634A1 (fr) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Anticorps dirigés contre le récepteur humain de mort programmée pd-1 |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| KR101001360B1 (ko) | 2008-06-16 | 2010-12-14 | (주)기가레인 | 전자 기기의 접지에 전기적으로 연결되는 인쇄회로기판 |
| PL2350129T3 (pl) | 2008-08-25 | 2015-12-31 | Amplimmune Inc | Kompozycje antagonistów PD-1 i sposoby stosowania |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| NZ717213A (en) | 2008-12-09 | 2017-10-27 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| PT2699264T (pt) | 2011-04-20 | 2018-05-23 | Medimmune Llc | Anticorpos e outras moléculas que ligam b7-h1 e pd-1 |
| WO2013014668A1 (fr) | 2011-07-24 | 2013-01-31 | Curetech Ltd. | Variants d'anticorps monoclonaux immunomodulateurs humanisés |
| ES2808152T3 (es) | 2011-11-28 | 2021-02-25 | Merck Patent Gmbh | Anticuerpos anti-PD-L1 y usos de los mismos |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| KR102129636B1 (ko) | 2012-05-31 | 2020-07-03 | 제넨테크, 인크. | Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| US10241115B2 (en) | 2013-12-10 | 2019-03-26 | Merck Sharp & Dohme Corp. | Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| MX390385B (es) | 2014-08-05 | 2025-03-20 | Cb Therapeutics Inc | Anticuerpos anti-pd-l1. |
| EP3254110B1 (fr) | 2015-02-03 | 2020-03-18 | Ventana Medical Systems, Inc. | Analyse histochimique pour évaluer l'expression du ligand de mort programmée 1 (pd-l1) |
| KR20170135860A (ko) | 2015-03-13 | 2017-12-08 | 싸이톰스 테라퓨틱스, 인크. | 항-pdl1 항체, 활성화 가능한 항-pdl1 항체, 및 이들의 사용 방법 |
| US20180155429A1 (en) | 2015-05-28 | 2018-06-07 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| AU2017225869A1 (en) | 2016-02-29 | 2018-09-06 | Foundation Medicine, Inc. | Methods of treating cancer |
| MX384929B (es) | 2016-04-07 | 2025-03-14 | Chemocentryx Inc | Reducción de carga tumoral mediante administración de antagonistas de ccr1 en combinación con inhibidores de muerte-1 programada (pd-1) o inhibidores de ligando-1 de muerte-1 programada (pd-l1). |
| TWI755395B (zh) * | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| KR102611270B1 (ko) | 2016-12-01 | 2023-12-08 | 리제너론 파마슈티칼스 인코포레이티드 | 면역-pet 영상화를 위한 방사성 표지된 항-pd-l1 항체 |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| CN111051535A (zh) * | 2017-06-13 | 2020-04-21 | 英国肿瘤有限公司 | 用于测定患有增生疾病的患者对使用靶向pd1/pd-l1路径的组分的药剂的治疗的敏感性的方法 |
| AU2018338441B2 (en) * | 2017-09-25 | 2025-08-14 | Memorial Sloan Kettering Cancer Center | Tumor mutational load and checkpoint immunotherapy |
| US20190284640A1 (en) * | 2018-03-15 | 2019-09-19 | Vanderbilt University | Methods and Systems for Predicting Response to Immunotherapies for Treatment of Cancer |
| JP7623281B2 (ja) * | 2018-11-15 | 2025-01-28 | パーソナル ゲノム ダイアグノスティクス インコーポレイテッド | 免疫療法で治療されたがん患者の応答の予測を改善する方法 |
-
2021
- 2021-08-25 MA MA71214A patent/MA71214A/fr unknown
- 2021-08-25 IL IL300328A patent/IL300328A/en unknown
- 2021-08-25 KR KR1020237010358A patent/KR20230056761A/ko active Pending
- 2021-08-25 US US18/042,441 patent/US20230323470A1/en active Pending
- 2021-08-25 WO PCT/US2021/047442 patent/WO2022046833A1/fr not_active Ceased
- 2021-08-25 AU AU2021332246A patent/AU2021332246A1/en active Pending
- 2021-08-25 CA CA3168743A patent/CA3168743A1/fr active Pending
- 2021-08-25 EP EP21773221.3A patent/EP4204592A1/fr active Pending
- 2021-08-25 JP JP2023513319A patent/JP2023540217A/ja active Pending
- 2021-08-25 MX MX2023002123A patent/MX2023002123A/es unknown
- 2021-08-25 CN CN202180053095.1A patent/CN116134155A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023540217A (ja) | 2023-09-22 |
| IL300328A (en) | 2023-04-01 |
| CA3168743A1 (fr) | 2022-03-03 |
| MX2023002123A (es) | 2023-03-15 |
| EP4204592A1 (fr) | 2023-07-05 |
| CN116134155A (zh) | 2023-05-16 |
| KR20230056761A (ko) | 2023-04-27 |
| AU2021332246A1 (en) | 2023-04-20 |
| AU2021332246A9 (en) | 2023-04-27 |
| US20230323470A1 (en) | 2023-10-12 |
| WO2022046833A1 (fr) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024002874A1 (es) | Inhibidores de kras | |
| MX2024015363A (es) | Compuestos de haloalquinilo para el tratamiento de cáncer | |
| MX2025011449A (es) | Inhibidores de kras | |
| CL2022001739A1 (es) | Compuestos tricíclicos sustituidos | |
| CO2021010415A2 (es) | Inhibidor jak y método de preparación del mismo | |
| MA44721A (fr) | Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer | |
| CY1124565T1 (el) | Αναστολεις πολυμερασης πολυ-adp ριβοζης (parp) | |
| MX2022000271A (es) | Inhibidores de la quinasa progenitora hematopoyetica 1 y usos de los mismos. | |
| CO2022015874A2 (es) | Inhibidores de cd38 | |
| CO6440596A2 (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero de rapamicina | |
| AR133985A1 (es) | Inhibidores de kras | |
| MA71214A (fr) | Méthodes de traitement du cancer par administration d'un inhibiteur de pd-1 | |
| CO2021014210A2 (es) | Compuestos de pirrol | |
| EP4149547A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
| EP3980069A4 (fr) | Méthodes de traitement d'une splénomégalie | |
| MA55084A (fr) | Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau | |
| EP4181671A4 (fr) | Modèles humanisés de souris pour l'infection par le sars-cov-2 | |
| EP3914701A4 (fr) | Méthodes de traitement de l'épilepsie par inhibition de la phosphodiestérase 4 (pde4) | |
| EA201990109A1 (ru) | Митохондриальные ингибиторы для лечения пролиферативных нарушений | |
| EP4384220A4 (fr) | Compositions et méthodes de traitement du cancer | |
| EP4262800A4 (fr) | Traitement de la glomérulopathie à c3 à l'aide d'un inhibiteur de c5a | |
| CL2023000648A1 (es) | Métodos para tratar enfermedades o afecciones mediadas por pde iv | |
| EP4444304A4 (fr) | Méthodes de traitement de l'immunodéficience primaire | |
| EP4320151A4 (fr) | Méthodes de traitement d'une inflammation | |
| HK40096277A (en) | Methods of treating cancer by administering a pd-1 inhibitor |